FitzGerald said he thinks the problem of increased risk also applies to Pfizer's Celebrex and Bextra.
 to the risk of heart attack or stroke," he said in an interview.
 But taking the drug off the market, he said, was the right thing, too.
 It was not stopped earlier because trial results did not find increased risk in the first 18 months of the trial, the FDA said.
 Gilmartin was clear that the trial should be halted and that the drug might have to be taken off the market.